Brain/Nervous System Cancer Clinical Trials


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1904 Tissue Bank for Benign and Malignant Tumors of the Nervous System
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ML29496 Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders (OHSU/Genentech) SUSPENDED
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: Trident EF-32 - Randomized, Phase III, Open-label Study of Tumor Treating Fields (Optune, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (COMING SOON)
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG BN007 A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (COMING SOON)
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Cancer Clinical Trials


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: JZLA EMBER - A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Primary/Site/Co-Investigator: Carl Nelson, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ACT 16106 Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients with ER Positive, HER2 Negative Primary Breast Cancer (COMING SOON)
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Bladder Cancer Clinical Trials


Study Title: D933RC00001- NIAGARA-A Phase III Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine & Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475 in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cander (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Primary/Site/Co-Investigator: Scott Perrapato, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A031501 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Endometrial Cancer Clinical Trials


Study Title: NRG GY018 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III OR IVA, Stage IVB or Recurrent Endometrial Cancer
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Gastrointestinal Cancer Clinical Trials


Study Title: EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1901, Use of digital PET scanning to identify lymphatic metastases in colon cancer
Primary/Site/Co Investigator: Peter Cataldo, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Head and Neck Cancer Clinical Trials


Study Title: MK-3475-689-A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Primary/Site/Co-Investigator: Mirabelle Sajisevi, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Kidney Cancer Clinical Trials


Study Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab:  A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
Primary/Site/Co-Investigator: Shahid Ahmed, MBBS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Leukemia Cancer Clinical Trials


Study Title: D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage
Primary/Site/Co-Investigator: Sakshi Jasra, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: PrE0905 Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (COMING SOON)
Primary/Site/Co-Investigator: Elvira Umyarova, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Cancer Clinical Trials


Study Title: D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC4/RTOG-3515)
Primary/Site/Co-Investigator: Nat Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG-LU005 Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
Primary/Site/Co-Investigator: Chris Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA5163 - A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (15-157 ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ECOG 4512 Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer (ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: CA209-73L: Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) (Coming Soon)
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lymphoma Clinical Trials


Study Title: A051701: Randomiized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoinnumotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas (Currently Suspended)
Primary/Site/Co-Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA4181 A Randomized 3-Arm Phase II Study Comparing 1)Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2) Bendamustine, Rituximab, High Dose Cytarabine, and Acalabrutinib (BR/CR-A) 3) Bendamustine, Rituximab, and Acalabrutinib (Br-A) in Patients Less Than or Equal to 70 Years Old with Untreated Mantle Cell Lymphoma (COMING SOON)
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Melanoma Clinical Trials


Study Title: S1801 - A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Primary/Site/Co-Investigator: Shahid Ahmed, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1912 - Using Circulating Tumor DNA (ctDNA) to Predict Minimal Residual Disease, Recurrent Disease, and Clinical Outcomes in Patients with High Risk Malignant Melanoma
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
To Learn More or Enroll: Call (802)656-4414 ext. 2

Ovarian Cancer Clinical Trials


Study Title: GOG 3018 The OVAL Study: A Randomized Controlled, Double Arm, Double Blind Multi-center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Prostate Cancer Clinical Trials


Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) or the Primary Tumor in Metastatic Prostate Cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Rectal/Anal Cancer Clinical Trials


Study Title: Wash U. Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA) (COMING SOON)
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA 2182 A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) (COMING SOON)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

About Us

Services

FAQs

Contact Us

 

Trials by Cancer Type

Click below to view open cancer trials by type. 

Brain/Nervous System Breast Bladder Endometrial Gastrointestinal Head and Neck Kidney Leukemia Lung Lymphoma Melanoma Ovarian Pediatric Prostate Rectal/Anal

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4414 ext. 2.